A new treatment for young people with depression
SKY-D is investigating whether ketamine is an effective treatment for young people with depression.
We are inviting young people aged 16 to 25 years, with moderate-to-severe depression, to take part in this research. Participants will divided into two groups. One group will receive a low dose of ketamine once a week for four weeks. The other group will receive a low dose of another medication, called midazolam, once a week for four weeks.
We hope that the results of this study will help us to provide the best possible care in the future for young people with depression.
Anticipated date that enrolment will close: November 2022
Who can take part
- Young people aged 16–25 years
- Current diagnosis of Major Depressive Disorder
- Treatment with either a stable dose of an antidepressant, or no antidepressant medication, for 2 or more weeks
- No history of psychosis or bipolar disorder
- No history of a ketamine use disorder of any severity, or presence of a substance use disorder of at least moderate severity within the past 6 months
What is involved for you
- Subcutaneous (this means “under the skin”) injections of medication once a week for four weeks
- Interviews and questionnaires
- Blood samples
- Weight and height
- Blood pressure